Date: 2011-09-02
Type of information: Nomination
Compound:
Company: AM-Pharma (The Netherlands)
Therapeutic area: Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 2 2011, AM-Pharma , a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for the treatment of severe inflammatory diseases, announced the appointment of Erik van den Berg, previously VP Business Development of AM-Pharma as CEO of the company.
Financial terms:
Latest news:
